A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls.
about
Systematic Review of Clozapine Cardiotoxicity.Inflammatory response to clozapine in the absence of myocarditis: case reportIvabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series.Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study.Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachIncidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia.Clozapine-Induced Myocarditis: A Case Report of an Adolescent Boy with Intellectual Disability.An update of safety of clinically used atypical antipsychotics.Probable clozapine-induced parenchymal lung disease and perimyocarditis: a case reportClozapine Associated with Autoimmune Reaction, Fever and Low Level Cardiotoxicity - A Case ReportCan medication management review reduce anticholinergic burden (ACB) in the elderly? Encouraging results from a theoretical model.Adverse effects of clozapine in older patients: epidemiology, prevention and management.Clozapine-induced myocarditis: is mandatory monitoring warranted for its early recognition?A state-wide quality improvement system utilising nurse-led clinics for clozapine management.Clozapine-induced myocarditis, a widely overlooked adverse reaction.Scoping review of research in Australia on the co-occurrence of physical and serious mental illness and integrated care.Clozapine-Associated Myocarditis: Case Report and Literature Review.Worldwide Differences in Regulations of Clozapine Use.Cardiovascular safety of antipsychotics: a clinical overview.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.C-reactive protein: an early critical sign of clozapine-related myocarditis.Clozapine-induced, dilated cardiomyopathy: a case reportClozapine-induced hypersensitivity myocarditis presenting as sudden cardiac death.Lessons Learned and Questions Raised by an Atypical Case of Clozapine-Induced Myocarditis.Transitioning patients taking clozapine from the public to private/GP shared-care setting: barriers and criteria.Evolution of troponin, C-reactive protein and eosinophil count with the onset of clozapine-induced myocarditis.Monitoring of long-term cardiac complications in patients receiving clozapine.Echocardiographic monitoring for clozapine cardiac toxicity: lessons from real-world experience.Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy.Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study.Successful clozapine re-challenge following myocarditis.Iatrogenic myocarditis-biomarkers, cardiovascular MRI and the need for early diagnosis.Clozapine-induced myocarditis: prescribe safely but do prescribe.Demonstrating the effectiveness of less restrictive care pathways for the management of patients treated with clozapine.Safety of long-term clozapine administration. Frequency of cardiomyopathy and hyponatraemia: two cross-sectional, naturalistic studies.Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review.Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.Clozapine-induced myocarditis: Two case reports and review of clinical presentation and recognition
P2860
Q30250192-C7E0B8E1-C070-4C0F-A2DE-6F44B81CBD36Q30490111-57A17A9F-A67B-4E62-8CB4-1BC73A6D0120Q33937346-68E6258A-5032-435F-A972-DB16943DEC9BQ34333212-6E5D4758-CCAF-4183-A406-BAA620BFD17DQ34464293-C3937E57-8BA5-4991-9D78-597A9A23EB5AQ35786006-C02A4C75-1C1C-48BF-BFCA-D8769A8739E8Q35918742-ED3CCFD6-4A8B-4884-B86A-ADC5EEE6669CQ36062184-30491740-28EE-414E-909D-D79FB5F42661Q36216518-C335CF74-D596-4BDC-ACAA-CF3DAEE29CBCQ37705282-267836E8-6029-4018-946C-4AFAAE1BACC8Q38115658-5A1D48D1-BAFB-41A3-9D11-5C1A2A92B0EFQ38171350-8D11F320-054E-4E85-A3F8-B2827CED8610Q38192640-69E512F0-B313-4B13-9064-B15F2E7CF54BQ38210463-9C587CB7-0DAE-4707-B58C-E53804F00334Q38417079-F3EFBF36-A70A-4BC1-9557-A3D87F1FBA98Q38556463-6C668859-0A27-4F16-A2EE-52A72943F43AQ38610589-3C6B56CC-4284-4D3D-A5B1-3B6FCE4B337BQ38736547-064D3C25-3830-4504-8F51-CE92F81AF4C8Q38757870-3F0883CC-E457-469B-8185-1A162A2F1CD0Q38815462-D04DCC5F-E154-43E0-942F-0A00AD47E11FQ38840211-7BC7FC6A-B97B-4912-B9AF-83B0F88FAFA5Q40082921-538BD931-B02F-4EE5-9A38-E7A99CB4EB19Q40138024-EDA88DDB-0A9C-4F21-BC46-740009B2CCE0Q41149948-99EAD449-EAF2-470F-9D09-984A3FF81DCFQ42026474-DD2EA9EF-C8AE-4823-86F1-979C926FF231Q42414574-BC1A5CBE-1914-4CFD-89F3-F81F57E28557Q42638874-A9E54A8F-17C5-44B5-B25B-4BB74F4FD6C4Q43785317-4E1D2EEE-D489-43BB-ADC1-FCEA9B108E44Q44410949-803D30DA-A4BA-49AB-8A9F-2D3F9B944D3EQ45833351-3EF35C1D-A653-4E93-96A4-5077924BE2ACQ46893940-677CBB1D-F615-4E1D-BB26-F73C2CA77323Q47590406-46AC56DC-E73E-4A29-9004-972500C1F09AQ47722361-66BC14D0-E777-4B3D-AA40-A6801F0E801CQ49331322-40FC71DA-6ABD-4F03-8E3E-6C72385CF66EQ50590325-BB154F91-52B7-42F4-A3ED-1AD16B2C32ABQ50698273-49EED99C-54FD-4F2B-A928-3BEE2F8CE900Q51335132-CE4FD569-6A1C-4A76-BCC8-1AD5455A193EQ52579281-B17EA266-6C4D-4A51-A18C-20D40B771573Q55232340-25EE4E10-3B08-4DA3-8470-1922EE6FEDF4Q58567904-C70385B6-45FC-41FA-A53D-7192383414EC
P2860
A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@ast
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@en
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@nl
type
label
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@ast
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@en
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@nl
prefLabel
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@ast
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@en
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@nl
P2860
P50
P1476
A new monitoring protocol for ...... s of 75 cases and 94 controls.
@en
P2093
Andrew J Taylor
Duncan J Topliss
P2860
P304
P356
10.3109/00048674.2011.572852
P577
2011-04-27T00:00:00Z